ELV · Full Picture

Elevance Health, Inc. — the full picture

Earnings window · 2026-06-24 to 2026-08-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

1. Membership / Enrollment Trends · Customers & concentrationPriority 55
   quote_verified
   Medicare Advantage membership was 1,897 (in thousands) as of June 30, 2026 and 2,255 (in thousands) as of June 30, 2025, a decrease of 358 (15.9%).
2. Liquidity and Cash Position · Liquidity & cash positionPriority 52
   quote_verified
   Consolidated cash, cash equivalents and investments in fixed maturity and equity securities were $38,773 at June 30, 2026.
3. Operating Cash Flow Trends · Cash flow generationPriority 52
   +4.3% cash (realized); quote_verified
   Operating cash flow for the six months ended June 30, 2026 was $6,245 and for the six months ended June 30, 2025 was $3,071.
4. Medicare Risk Adjustment / RADV · UnclassifiedPriority 49
   1 forward row(s); quote_verified
   In connection with the notice the Company received in February 2026 from CMS regarding certain Medicare Advantage risk adjustment data submission requirements related to diagnosis codes for dates of service 2015 through April 2023, CMS provided a series of steps required to be completed by July 31, 2026 in order to avoid sanctions.
5. Capital Resources and Facilities · Debt, leverage & refinancingPriority 48
   quote_verified
   We have a shelf registration statement to register an unlimited amount of any combination of debt or equity securities.
6. Interest Rate and Refinancing Exposure · Interest ratesPriority 48
   qualitative only
7. Capital Return Program · Buybacks & dividendsPriority 47
   2 sources (news, sec_filing); quote_verified
   Declared quarterly dividend: $1.72 per share.
8. OBBBA Federal Changes · UnclassifiedPriority 47
   qualitative only
9. Outstanding Indebtedness and Ratings · Debt, leverage & refinancingPriority 46
   quote_verified
   Our consolidated debt-to-capital ratio was 40.8% as of June 30, 2026 and 42.1% as of December 31, 2025.
10. IRA Drug & Subsidy Impacts · Compliance & policy costsPriority 44
    qualitative only
11. Transformation Program · Strategic & business-model shiftsPriority 44
    quote_verified
    In the first quarter of 2026, management initiated the 2026 - 2027 Operating Model Transformation Program to streamline decision-making, simplify organizational structures, and enhance the use of advanced technologies.
12. Accrued Legal and Regulatory · Regulatory action & investigationsPriority 42
    qualitative only

Threads by pillar

Revenue & Demand Priority 70 · 5 threads

• Membership / Enrollment TrendsPriority 55 · Filing
• Vision Membership GrowthPriority 27 · Filing
• Pricing TrendsPriority 39 · Filing
• Revenue Performance and MixPriority 38 · News
• Geographic Market CommentaryPriority 29 · Filing

Costs & Margins Priority 52 · 3 threads

• Shareholders' Net Income and EPS DeclinePriority 39 · Filing
• Operating Expense TrendsPriority 34 · Filing
• Medical Cost TrendsPriority 33 · Filing

Capital & Balance Sheet Priority 79 · 7 threads

• Liquidity and Cash PositionPriority 52 · Filing
• Liquidity Outlook and Funding SourcesPriority 30 · Filing
• Capital Resources and FacilitiesPriority 48 · Filing
• Outstanding Indebtedness and RatingsPriority 46 · Filing
• Operating Cash Flow TrendsPriority 52 · Filing
• Capital Return ProgramPriority 47 · News, Filing
• Net Investment Income TrendsPriority 30 · Filing

Strategy & Portfolio Priority 44 · 1 thread

• Transformation ProgramPriority 44 · Filing

Legal, Regulatory & Policy Priority 59 · 4 threads

• Accrued Legal and RegulatoryPriority 42 · Filing
• Regulatory Statutory Capital (RBC) CompliancePriority 21 · Filing
• IRA Drug & Subsidy ImpactsPriority 44 · Filing
• BCBSA Antitrust LitigationPriority 27 · Filing

Macro & Market Conditions Priority 48 · 1 thread

• Interest Rate and Refinancing ExposurePriority 48 · Filing

Unclassified Priority 87 · 5 threads

• Medicare Risk Adjustment / RADVPriority 49 · Filing
• OBBBA Federal ChangesPriority 47 · Filing
• PBM Reform LegislationPriority 42 · Filing
• Operating Gain DeclinePriority 41 · Filing
• CarelonRx Outsourcing and Volume/Cost TrendsPriority 40 · Filing

Expected impact by metric